# ALLO-647

Source: https://onco.cc/drugs/allo-647/  
OnCo record `allo-647` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

ALLO-647 is an experimental monoclonal antibody from Allogene Therapeutics in phase 2 trials for diffuse large B-cell lymphoma, aimed at CD52.

## Summary

ALLO-647 is a monoclonal antibody developed by Allogene Therapeutics. Its target is CD52 (the sponsor names CD52). The sponsor states: Monoclonal antibody that recognises the CD52 antigen; used as part of a lymphodepletion regimen (with fludarabine and cyclophosphamide) ahead of allogeneic CAR T-cell dosing. ClinicalTrials.gov describes the intervention as: ALLO-647 is a monoclonal antibody that recognizes a CD52 antigen. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in diffuse large B-cell lymphoma. The largest, NCT04416984, plans to enrol 160 participants with primary completion expected 2029-02. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.

## Fields

- Kind: Treatment
- Status: phase-2
- Last checked: 2026-09-11
- Tags: pipeline; ctgov-ingest
- Modality: monoclonal antibody
- Mechanism: Monoclonal antibody that recognises the CD52 antigen; used as part of a lymphodepletion regimen (with fludarabine and cyclophosphamide) ahead of allogeneic CAR T-cell dosing.

## Sources

- ClinicalTrials.gov: trials of ALLO-647: https://clinicaltrials.gov/search?intr=ALLO-647

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- targets: [CD52](https://onco.cc/targets/cd52/)
- companies: [Allogene Therapeutics](https://onco.cc/companies/allogene/)
- trials: [Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)](https://onco.cc/trials/nct04416984/)

---
JSON: https://onco.cc/api/v1/entities/allo-647.json